Preparations of next generation monoclonal antibodies (issues and prospects)

Abstract

The article provides the information on issues related to the clinical use of preparations of monoclonal antibodies (MAb), and the prospects for developing preparations based on modified MAbs. MAb preparations based on recombinant proteins show the consistency of physical and chemical properties as well as high specificity. New class of preparations based on MAbs show great potential of targeted therapeutic influence on important pathogenetic mechanisms of disease development. It has proved to be successful against severe chronic diseases such as autoimmune cancer, infectious and allergic diseases, as well as in transplantation for the treatment and prevention of transplant rejection. The development and manufacture of MAb preparations based on a whole immunoglobulin molecule, as well as preparations of modified antibodies with a specific set of functions associated with individual structural elements of the molecule is now possible due to genetic engineering and transgenic animals technologies. Preparations based on modified MAb can exist in

Keywords

• лекарственные препараты
• моноклональные антитела
• препараты модифицированных моноклональных антител
• иммуноглобулин класса g
• нежелательная иммуногенность
• конъюгированные моноклональные антитела
• технология генной инженерии
• биотехнологические препараты